Centessa Pharmaceuticals

2 months ago · newsfilecorp.com

Vancouver, British Columbia--(Newsfile Corp. - July 27, 2026) - Global UAV Technologies Ltd. (CSE: UAV) (OTC Pink: YRLLF) (FSE: 1OZ) (the "Company") is pleased to announce that it is has entered into a letter of intent (the "LOI") dated July 27, 2026 with Nexus Peptide Sciences Inc. ("Nexus"), a private corporation existing under the laws of British Columbia, pursuant to which the Company would acquire (the "Transaction") all of the outstanding securities of Nexus from the securityholders of Nexus (collectively, the "Nexus Shareholders").

3 months ago · globenewswire.com

BOSTON and LONDON, June 22, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, which entered into a definitive agreement on March 31, 2026 relating to its proposed acquisition by Eli Lilly and Company (“Lilly”), through a wholly owned subsidiary, today announced that the High Court of Justice of England and Wales has approved the proposal for Lilly to acquire Centessa for $38.00 in cash per share plus one non-transferable contingent value right (“CVR”) that entitles the holder to receive up to an aggregate of $9.00 subject to the achievement of three milestones, for a total transaction value of approximately $7.8 billion (the “Transaction”).

5 months ago · prnewswire.com

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws

5 months ago · businesswire.com

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Centessa Pharmaceuticals plc (NasdaqGS: CNTA) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Centessa will receive $38.00 in cash per share plus one non-transferrable contingent value right entitling the holder to receive up to an aggregate of.

6 months ago · globenewswire.com

MILWAUKEE, April 07, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Centessa (NASDAQ: CNTA) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Lilly.

6 months ago · prnewswire.com

NEW YORK, April 1, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Centessa Pharmaceuticals plc (NASDAQ: CNTA) related to its sale to Eli Lilly and Company.

6 months ago · fool.com

Centessa possesses a promising sleep medicine pipeline. The clinical-stage company's experimental therapies have blockbuster potential.

6 months ago · schaeffersresearch.com

Centessa Pharmaceuticals PLC (NASDAQ:CNTA) shares are surging today, last seen 44.4% higher to trade at $39.90 on news that Eli Lilly (LLY) will acquire the company for $6.3 billion.

6 months ago · invezz.com

Eli Lilly has agreed to acquire Centessa Pharmaceuticals in a deal valued at up to $7.8 billion, marking a significant expansion of the drugmaker's neuroscience portfolio into sleep medicine. Under the terms announced Tuesday, Lilly will pay $38 per share in cash upfront, valuing Centessa at approximately $6.3 billion.

6 months ago · cnbc.com

Eli Lilly will pay up to $7.8 billion to acquire Centessa Pharmaceuticals. Centessa is developing orexin agonists to treat narcolepsy and excessive drowsiness.